Company / Free Cash Flow
Revolution Medicines, Inc. Free Cash Flow History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$913.7M
FY2025
5-year range
-$913.7M / -$52.2M
FY2021-FY2025
Trend
-60.9%
vs FY2024
Sector context
#192 of 194
Health Care
What the data says
Among 194 Health Care companies, Revolution Medicines, Inc. is in the bottom 1% for free cash flow. Free Cash Flow has declined for 5 consecutive years, from -$286,000 in FY2020 to -$914M in FY2025.
Based on SEC 10-K filings.
-$914M in FY2025.
Declined from -$358M to -$914M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 1% in Health CareTop 99% of 194This company -$913.7M Sector average $470.8M
▼
-294.1% below sector average
Key checks
Key Insights
- Revolution Medicines, Inc.'s free cash flow has declined for 5 consecutive years.
- In FY2025, free cash flow decreased 60.9% year-over-year.
- Ranks #192 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$913.7M | -60.9% |
| FY2024 | -$567.7M | -58.5% |
| FY2023 | -$358.3M | -247.9% |
| FY2022 | -$103.0M | -97.3% |
| FY2021 | -$52.2M | -18153.5% |
| FY2020 | -$286.0K | +99.5% |
| FY2019 | -$52.2M | -18153.5% |
| FY2018 | -$286.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026